TherapeuticsMD posts Q3 net income of $50K vs year-ago loss; license revenue up 43%

TherapeuticsMD, Inc.

2025-Q3 EPS reported $0.00 revenue$2,129,000

Net income from continuing operations was $50K ($0.00 per share) vs net loss of $567K ($0.05) in Q3 2024.
License revenue from Mayne Agreement rose 43% to $784K from $547K year-over-year.
Total operating expenses decreased 2.1% to $1,646K, roughly flat from prior year.
Company evaluating strategic alternatives including M&A, sale of assets; no timetable set.
Cash and cash equivalents stood at $7.1 million as of September 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.